MA31435B1 - Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2 - Google Patents

Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2

Info

Publication number
MA31435B1
MA31435B1 MA32406A MA32406A MA31435B1 MA 31435 B1 MA31435 B1 MA 31435B1 MA 32406 A MA32406 A MA 32406A MA 32406 A MA32406 A MA 32406A MA 31435 B1 MA31435 B1 MA 31435B1
Authority
MA
Morocco
Prior art keywords
norobillin
antibody anti
inhibitor
malignant metastases
malignant
Prior art date
Application number
MA32406A
Other languages
Arabic (ar)
English (en)
Inventor
Yan Wu
Wei-Ching Liang
Ryan Jefferson Watts
Anil Durgadas Bagri
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA31435B1 publication Critical patent/MA31435B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des antagonistes de la nrp2, tels que des anticorps anti-nrp2 et leur utilisation dans la prévention et le traitement de métastases tumorales.
MA32406A 2007-05-17 2009-12-07 Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2 MA31435B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/069179 WO2008143665A1 (fr) 2007-05-17 2007-05-17 Inhibition de métastases tumorales par des anticorps anti-neuropiline 2

Publications (1)

Publication Number Publication Date
MA31435B1 true MA31435B1 (fr) 2010-06-01

Family

ID=39301228

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32406A MA31435B1 (fr) 2007-05-17 2009-12-07 Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2

Country Status (16)

Country Link
US (2) US8648173B2 (fr)
EP (1) EP2152307B1 (fr)
JP (1) JP5745840B2 (fr)
KR (1) KR101520115B1 (fr)
CN (1) CN101754771B (fr)
AU (1) AU2007353778B9 (fr)
BR (1) BRPI0721660A2 (fr)
CA (1) CA2687247A1 (fr)
CR (1) CR11126A (fr)
ES (1) ES2469743T3 (fr)
IL (1) IL202005A (fr)
MA (1) MA31435B1 (fr)
MX (1) MX2009012421A (fr)
NO (1) NO20093542L (fr)
UA (1) UA99292C2 (fr)
WO (1) WO2008143665A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2162552A4 (fr) * 2007-05-11 2010-06-30 Univ Johns Hopkins Biomarqueurs pour mélanomes
EP2488874A4 (fr) * 2009-10-13 2013-08-14 Univ Johns Hopkins Biomarqueur d'identification de cellules tumorales de mélanome
ES2708565T3 (es) 2013-03-15 2019-04-10 Atyr Pharma Inc Conjugados de Fc-histidil-ARNt sintetasa
WO2015095686A1 (fr) 2013-12-20 2015-06-25 Trustees Of Boston University Analyses et méthodes associées au traitement de mélanomes
EP3148564B1 (fr) 2014-06-02 2020-01-08 Children's Medical Center Corporation Procédés et compositions pour une immunomodulation
CA3060514A1 (fr) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions et procedes pour le traitement d'inflammation pulmonaire
CN111051346A (zh) 2017-05-31 2020-04-21 斯特库伯株式会社 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
KR20200026209A (ko) * 2017-06-06 2020-03-10 주식회사 에스티큐브앤컴퍼니 Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
AU2019247511B2 (en) * 2018-04-06 2025-10-16 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
CA3156803A1 (fr) * 2019-10-03 2021-04-08 Atyr Pharma, Inc. Compositions et methodes comprenant des anticorps anti-nrp2
MX2023001366A (es) * 2020-07-31 2023-04-26 Pinetree Therapeutics Inc Péptidos de fusión de neuropilina y enzima conviertidora de angiotensina 2 para el tratamiento de infecciones virales.
CN114277152A (zh) * 2022-01-14 2022-04-05 张赟建 用于预测甲状腺乳头状癌淋巴结转移的特异性基因及制备方法
CN114262683B (zh) * 2022-03-01 2022-06-17 中国科学院动物研究所 一种表达vegfr3 d2多肽的细菌制剂及其构建方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
PT971959E (pt) 1997-04-07 2006-05-31 Genentech Inc Anticorpos humanizados e metodos para formar anticorpos humanizados
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
CA2313607A1 (fr) 1997-12-09 1999-06-17 Children's Medical Center Corporation Fonction et utilisation de l'antagoniste du recepteur de la neuropiline
EP1037981A1 (fr) * 1997-12-09 2000-09-27 Children's Medical Center Corporation Inhibiteurs solubles du facteur de croissance de l'endothelium vasculaire et leurs utilisations
US6417169B1 (en) * 1998-04-23 2002-07-09 Genesense Technologies Inc. Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to inhibit cell growth
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
CA2488441C (fr) 2002-06-03 2015-01-27 Genentech, Inc. Bibliotheques de phages et anticorps synthetiques
US20080057028A1 (en) 2002-10-02 2008-03-06 Institute Nationale De La Sante Et De La Recherche Medicale (Inserm) Vegf-C or Vegf-D Materials and Methods for Stimulation of Neural Stem cells
EP1439192A1 (fr) * 2003-01-15 2004-07-21 Xerion Pharmaceuticals AG Inhibiteurs de neuropilin-1
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)

Also Published As

Publication number Publication date
CA2687247A1 (fr) 2008-11-27
CN101754771A (zh) 2010-06-23
IL202005A0 (en) 2010-06-16
NO20093542L (no) 2010-02-12
ES2469743T3 (es) 2014-06-18
IL202005A (en) 2014-11-30
US20100172921A1 (en) 2010-07-08
UA99292C2 (uk) 2012-08-10
KR101520115B1 (ko) 2015-05-13
MX2009012421A (es) 2009-12-01
US20140234312A1 (en) 2014-08-21
EP2152307B1 (fr) 2014-04-16
HK1134040A1 (en) 2010-04-16
JP5745840B2 (ja) 2015-07-08
AU2007353778B9 (en) 2014-04-03
CN101754771B (zh) 2015-03-04
EP2152307A1 (fr) 2010-02-17
AU2007353778B2 (en) 2013-11-07
BRPI0721660A2 (pt) 2013-01-22
KR20100018567A (ko) 2010-02-17
US8648173B2 (en) 2014-02-11
CR11126A (es) 2010-05-19
WO2008143665A1 (fr) 2008-11-27
AU2007353778A1 (en) 2008-11-27
US8920805B2 (en) 2014-12-30
HK1144556A1 (en) 2011-02-25
JP2010527350A (ja) 2010-08-12

Similar Documents

Publication Publication Date Title
MA31435B1 (fr) Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2
MA33256B1 (fr) Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
MA30384B1 (fr) Therapies combinatoires
EA200971131A1 (ru) Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
MA34780B1 (fr) Anticorps se liant de façon préférentielle au domaine extracellulaire 4 de csf1r human et leur utilisation
CY1109985T1 (el) Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων
NO20081636L (no) FAP - inhibitorer
TW201713640A (en) Bruton's tyrosine kinase inhibitors
MA31167B1 (fr) Inhibiteurs de l'activite de akt
MA29369B1 (fr) Dosage fixe d'anticorps anti-her
EA201070247A1 (ru) Ингибиторы протеасом
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
EA201300246A1 (ru) Ингибиторы тирозинкиназы брутона
MA30353B1 (fr) Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes.
BR112013008140A8 (pt) "compostos imidazotriazinona".
MA34753B1 (fr) Compositions et procédés de traitement dans des applications cliniques à large spectre, indifférenciées ou mixtes
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
MY151191A (en) Novel antibodies
CO6571886A2 (es) Antagonistas de pcsk9
MA34881B1 (fr) Anticorps et immunoconjugués anti-mésothéline
EA200870409A1 (ru) Антагонисты киназы pi3
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
MA32226B1 (fr) Compositions et leurs procedes de preparation et d'utilisation